PTK7 and neoplasm: Work targeting PTK7 using a targeted antibody–drug conjugate containing humanized anti-PTK7 monoclonal antibody in conjunction with cytotoxic agents showed that PTK7-targeted treatment induced tumor regression that outperformed traditional chemotherapy in a mouse model of NSCLC using patient-derived xenografts in SCID mice [69].